Grassley backs FDA “whistleblower”

Executive Summary

Senate Finance Committee Chairman Charles Grassley (R-Iowa) asks FDA in Nov. 29 letter to explain allegations that Office of Drug Safety Associate Director for Science David Graham, MD, will face compulsory reassignment or be fired for criticism of the agency at Vioxx hearing (1"The Pink Sheet" Nov. 22, 2004, p. 4). A Nov. 24 letter from Grassley calls for an HHS Office of Inspector General investigation of reports that two FDA managers sought to preemptively discredit Graham to a whistleblower protection organization. "It appears that these activities may have been coordinated by FDA management and may have involved the misuse of government resources," Grassley says...